Weekly epirubicin for breast cancer with liver metastases and abnormal liver biochemistry.
Thirty-six consecutive patients with breast cancer and liver metastases with abnormal liver biochemistry were treated with epirubicin 25 mg m-2 i.v. weekly. No dose modification was made for abnormal liver biochemistry, but dose intensity was adjusted by delaying treatment according to myelosuppression. The UICC overall response rate according to UICC criteria was 11/36 (30%) and median response duration was 27 weeks. Liver biochemistry improved in a further seven patients. Treatment was well tolerated. Epirubicin given in this way is effective in patients with breast cancer and liver metastases. An initial deterioration in liver biochemistry may occur before there is a response to epirubicin.
Twelves
C J
CJ
Imperial Cancer Research Fund Clinical Oncology Unit, Guy's Hospital, London, UK.
O'Reilly
S M
SM
Coleman
R E
RE
Richards
M A
MA
Rubens
R D
RD
D000328:Adult; D000368:Aged; D001219:Aspartate Aminotransferases / Q000097:blood; D001663:Bilirubin / Q000097:blood; D001943:Breast Neoplasms / Q000097:blood / Q000188:drug therapy*; D015251:Epirubicin / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000097:blood / Q000556:secondary*; D008875:Middle Aged; D013997:Time Factors
D015251:Epirubicin; D001219:Aspartate Aminotransferases; D001663:Bilirubin